Table 1.
Phase of clinical trials for emerging therapeutic options for inflammatory bowel
|
Treatment
|
UC
|
CD
|
Treatment
|
UC
|
CD
|
Treatment
|
UC
|
CD
|
Treatment
|
UC
|
CD
|
| Anti-IL | Anti-integrin | JAK inhibitors | Other therapies | ||||||||
| Rizankinumab | III | III | Ontamalimab | III | II | Upadacitinib | III | III | AVX-470 | I | |
| Mirikizumab | III | II | Etrolizumab | III | III | Filgotinib | III | III | Laquinimod | - | II |
| Brazikumab | II | III | Abrilumab | II | II | Peficitinib | II | - | Cobitolimod | III | - |
| Guselkumab | II | III | AJM300 | III | - | TD-1473 | II | II | BL-7040 | II | - |
| Briakinumab | - | II | Cytokine blockade | Modulation of SIP1 | Phosphatidylcholine | III | - | ||||
| PTG‑200 | - | II | Vercirnon | - | III | Ozanimod | III | III | Apremilast | II | - |
| Secukinumab | - | II | Eldelumab | II | II | Etrasimod | III | - | Mongersen | - | II |
| Brodalumab | - | II | GSK3050002 | I | - | Amiselimod | - | II | GATA3 DNAzyme | II | - |
| PF-04236921 | - | II | KRP-203 | II | - | STNM01 | II | ||||
UC: Ulcerative colitis; CD: Crohn´s disease; IL: Interleukin; JAK: Janus kinase; S1P1: Sphingosine-1-phosphate.